"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1" by Philip J. Mease

Article

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2017)

Philip J. Mease, University of Washington
Désirée van der Heijde, Leiden University Medical Center
Christopher T. Ritchlin, University of Rochester
Masato Okada, International University, Cambodia
Raquel S. Cuchacovich, Eli Lilly and Company
Catherine L. Shuler, Eli Lilly and Company
Chen-Yen Lin, Eli Lilly and Company
Daniel K. Braun, Eli Lilly and Company
Chin H. Lee, Eli Lilly and Company
Dafna D. Gladman, Toronto Western Hospital

Link

Disciplines

Publication Date

January 1, 2017

Citation Information

Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, Masato Okada, et al.. "Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1" (2017)
Available at: http://works.bepress.com/philip-mease/67/